This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Welling, P. G. Articles by Craig, W. A. Search for Related Content PubMed PubMed Citation Articles by Welling, P. G. Articles by Craig, W. A.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1977 March; 11(3): 462-469
Copyright © 1977 American Society for Microbiology. All Rights Reserved.

Bioavailability of Tetracycline and Doxycycline in Fasted and Nonfasted Subjects

^* University of Wisconsin Center for Health Sciences, School of Pharmacy, Madison, Wisconsin 53706
Department of Medicine, and the Veterans Administration Hospital, Madison, Wisconsin 53706

ABSTRACT

The influence of various test meals and fluid volumes on the relative bioavailability of commercial formulations of doxycycline hyclate and tetracycline hydrochloride was studied in healthy human volunteers. Serum levels of tetracycline were uniformly reduced by approximately 50% by all test meals, whereas serum levels of doxycycline were reduced by 20%. The reduction of tetracycline serum levels will likely be of clinical significance. The bioavailability of each drug was almost identical from an oral solution and from capsules in fasted subjects. The rate of doxycycline absorption was reduced when capsules were administered with a small volume of water, but the overall efficiency of absorption of both drugs was essentially independent of co-administered fluid volume. The use of 8-h serum data provides a reliable estimate of drug bioavailability for tetracycline and, to a lesser extent, for doxycycline.

This article has been cited by other articles:

• Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265 [Abstract] [Full Text]  
• Newton, P. N., Chaulet, J.-F., Brockman, A., Chierakul, W., Dondorp, A., Ruangveerayuth, R., Looareesuwan, S., Mounier, C., White, N. J. (2005). Pharmacokinetics of Oral Doxycycline during Combination Treatment of Severe Falciparum Malaria. Antimicrob. Agents Chemother. 49: 1622-1625 [Abstract] [Full Text]  
• Cianfrocca, M., Cooley, T. P., Lee, J. Y., Rudek, M. A., Scadden, D. T., Ratner, L., Pluda, J. M., Figg, W. D., Krown, S. E., Dezube, B. J. (2002). Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. JCO 20: 153-159 [Abstract] [Full Text]  
• Rudek, M. A., Figg, W. D., Dyer, V., Dahut, W., Turner, M. L., Steinberg, S. M., Liewehr, D. J., Kohler, D. R., Pluda, J. M., Reed, E. (2001). Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. JCO 19: 584-592 [Abstract] [Full Text]  
• Ives, T. J., Marston, E. L., Regnery, R. L., Butts, J. D., Majerus, T. C. (2000). In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected Vero cell monolayers. J Antimicrob Chemother 45: 305-310 [Abstract] [Full Text]